n-methylisoindigotin has been researched along with Leukemia, Myeloid, Acute in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, YC; Lee, CC; Lee, YL; Lin, CP; Liu, HE; Wang, GC | 1 |
1 other study(ies) available for n-methylisoindigotin and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Humans; Indoles; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Proto-Oncogene Proteins c-bcl-2; Telomerase; Tumor Cells, Cultured; Up-Regulation | 2010 |